Sugi Predict

Sugi Predict / Targets / PRSS1

PRSS1

Serine protease 1 · P07477 · PRSS1 on Sugi Atlas →

222,204 patent compounds predicted against PRSS1, 131,428 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Otamixaban Otamixaban (SCHEMBL52983) 1.00 18/20
SCHEMBL73946 SCHEMBL73946 0.55 13/20
SCHEMBL91350 SCHEMBL91350 0.48 11/20
SCHEMBL34160 SCHEMBL34160 0.56 9/20
SCHEMBL107649 SCHEMBL107649 0.71 8/20
SCHEMBL34107 SCHEMBL34107 0.54 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL33976) 0.50 8/20
SCHEMBL35916 SCHEMBL35916 0.49 8/20
SCHEMBL33646 SCHEMBL33646 0.48 8/20
Pentamidine Pentamidine (SCHEMBL3227) 1.00 7/20
Pentamidine Pentamidine (SCHEMBL3329) 0.96 7/20
SCHEMBL48986 SCHEMBL48986 0.57 7/20
SCHEMBL107413 SCHEMBL107413 0.55 7/20
SCHEMBL29945 SCHEMBL29945 0.48 7/20
SCHEMBL48418 SCHEMBL48418 0.47 6/20
Benzamidine Benzamidine (SCHEMBL61379) 0.94 5/20
SCHEMBL49594 SCHEMBL49594 0.67 5/20
SCHEMBL89386 SCHEMBL89386 0.59 4/20
SCHEMBL105982 SCHEMBL105982 0.53 4/20
SCHEMBL109433 SCHEMBL109433 0.52 4/20

Clinical trials — most relevant to PRSS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 PHASE2/PHASE3UNKNOWN
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus PHASE2UNKNOWN
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients PHASE2WITHDRAWN
STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care PHASE2UNKNOWN
A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis PHASE1/PHASE2COMPLETED
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia PHASE2COMPLETED
Effects of Topical SLPI on Skin Wounds PHASE1COMPLETED
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) EARLY_PHASE1UNKNOWN
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID nanRECRUITING
Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids nanWITHDRAWN
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
PAR Family Polymorphisms and Placental Invasion Disorders nanUNKNOWN
Germline Mutations in Pancreatic Adenocarcinoma nanCOMPLETED
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
Quebec Pancreas Cancer Study nanUNKNOWN
ACE2 Gender Differences in Stroke With COVID-19 nanCOMPLETED
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study nanWITHDRAWN
French National Cohort of Patients With PRSS1 Mutations nanRECRUITING
HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients nanCOMPLETED
MMP Polymorphisms and Acute Coronary Syndromes nanCOMPLETED
Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP ) nanCOMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
Cardiac Injury in COVID-19: a Pathology Study nanUNKNOWN
MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients nanUNKNOWN
SLPI for Prostate Cancer nanUNKNOWN
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity nanWITHDRAWN
Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases nanRECRUITING
Impact of the Genetic Polymorphism on COVID-19 in Egypt nanUNKNOWN
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a PRSS1 binder may also engage these)

ProteinNameSimilarity
Q8NHM4 — 0.997 Q8NHM4 →
Q9QUK9 — 0.994 Q9QUK9 →
P00763 — 0.994 P00763 →
Q9R0T7 — 0.994 Q9R0T7 →
P07146 — 0.993 P07146 →
PRSS2 Trypsin-2 0.993 landscape →
P06871 — 0.992 P06871 →
P35031 — 0.991 P35031 →
Q29463 — 0.989 Q29463 →
Q90629 — 0.989 Q90629 →
P00762 — 0.988 P00762 →
P70059 — 0.987 P70059 →
P16049 — 0.987 P16049 →
P08426 — 0.987 P08426 →
P06872 — 0.986 P06872 →
Q91041 — 0.985 Q91041 →
P19799 — 0.981 P19799 →
Q90628 — 0.980 Q90628 →
P32822 — 0.980 P32822 →
P80646 — 0.979 P80646 →
P12788 — 0.978 P12788 →
A1KXI1 — 0.978 A1KXI1 →
P32821 — 0.977 P32821 →
P00760 — 0.977 P00760 →
P51588 — 0.977 P51588 →
Q90627 — 0.976 Q90627 →
P35032 — 0.976 P35032 →
P08218 — 0.973 P08218 →
CTRB1 Chymotrypsinogen B 0.972 landscape →
P00761 — 0.972 P00761 →